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excess of $1 billion. CONCLUSION: The economic value of
newer technologies with longer term survivorship will play an
important role in meeting the growing demand and ﬁnancial
burden of THA. Improved THA survivorship will also enhance
patients’ quality of life. Therefore, the longevity of these innova-
tive implants will be an important factor in evidence based deci-
sion making and economic evaluation of THA.
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OBJECTIVE: To estimate the life-time cost-effectiveness (CE) of
abatacept in patients with active RA and inadequate response to
MTX or anti-TNFs. METHODS: We developed a patient-level
simulation model to depict progression of functional disability
over time. Functional disability was expressed in terms of the
Health Assessment Questionnaire Disability Index (HAQ-DI).
Health-state utilities and medical-care costs were assumed to
depend on HAQ DI scores. The model separately estimated CE
using data from three phase III clinical trials: 1) abatacept in
patients with inadequate response to MTX (AIM); 2) abatacept
in patients with inadequate response to anti-TNFs (ATTAIN);
and 3) abatacept or inﬂiximab in patients with inadequate
response to MTX (BMS-IM101043). Cost-effectiveness of abata-
cept was examined in terms of the incremental cost (2006 Cana-
dian dollars) per quality-adjusted life-year (QALY). RESULTS: 1)
AIM trial: On a lifetime basis, abatacept was estimated to yield
an average of 1.4 additional QALYs per patient vs. MTX at a
mean incremental cost of $54,331; the estimated CE of abatacept
was $39,604 (95% CI: $38,746, $41,384) per QALY gained; 2)
ATTAIN: abatacept yielded an average of 1.2 additional QALY
vs. oral DMARDs alone at a mean incremental cost of $50,141;
estimated CE of abatacept was $42,021 (95% CI: $40,954,
$43,256) per QALY; 3) trial 043: Relative to placebo, abatacept
yielded an average of 1.58 additional QALY at a mean incremen-
tal cost of $58,351; incremental CE of abatacept was $37,094
($35,535, $38,727) per QALY; inﬂiximab yielded an average of
1.24 additional QALY at a mean incremental cost of $53,305;
incremental CE of inﬂiximab was $43,247 ($40,845, $44,587)
per QALY. Relative to inﬂiximab, the incremental CE of abata-
cept was about $14,841 per QALY. CONCLUSION: Abatacept
is cost-effective in patients with active RA and inadequate
response to DMARD or anti-TNF therapy and also highly cost
effective relative to inﬂiximab.
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OBJECTIVE: To estimate the life-time cost-effectiveness of
abatacept relative to rituximab in patients with active rheuma-
toid arthritis (RA) and an inadequate response to anti-tumor
necrosis factor (anti-TNF) therapy. METHODS: We used a pre-
viously published patient level simulation model to depict pro-
gression of functional disability over time in people with active
RA. Health-state utilities and medical-care costs were projected
based on the Health Assessment Questionnaire Disability Index
(HAQ-DI) scores. RA patients who were inadequate responders
to anti-TNF therapy were assumed to receive abatacept or ritux-
imab in combination with MTX on a lifelong basis or until
therapy discontinuation due to lack of efﬁcacy or side effects.
HAQ-DI improvement at 6 months (-25% versus -22%), after
adjustments for control drug response, were derived from two
comparable abatacept and rituximab Phase III trials. The cost of
abatacept (or rituximab) treatment was estimated at $18,480 (or
$20, 500) for the ﬁrst year, and at $17,160 (or $20,500) for
subsequent years. Costs and health effects were discounted at 5%
annually. All costs were expressed in 2007 Canadian Dollars.
First order and second order uncertainty were considered.
RESULTS: The reference case in the analysis is women aged
55–64 years. Relative to placebo, abatacept therapy was esti-
mated to yield an average of 1.07 (95% conﬁdence interval
[CI] = 1.00, 1.14) additional quality adjusted life years (QALY)
per patient, at a mean incremental cost of $45,875 (95%
CI = $42,795, $47,773); rituximab therapy was estimated to
yield an average of 0.94 (95% CI = 0.82, 1.05) additional QALY
per patient, at a mean incremental cost of $51,101 (95%
CI = $45,835, $57,175). Life time treatment with abatacept was
estimated to be a dominant strategy compared with rituximab,
primarily due to lower treatment costs and better HAQ improve-
ment. The study ﬁndings were robust under uncertainty analyses.
CONCLUSION: Abatacept therapy would be economically
attractive from a Canadian payer perspective.
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OBJECTIVE: The objective of this study was to access the cost-
effectiveness of rituximab (RTX) for the treatment of rheumatoid
arthritis (RA) in Taiwan from a payer’s (Bureau of National
Health Insurance [BNHI]) perspective. METHODS: A cost-
effectiveness model was developed to simulate the long-term
clinical outcome and cost impact for a cohort of 10,000 RA
patients over the lifetime. The main comparator was current
treatment arm, which included etanercept +methotrexate
(ETAN + MTX), adalimumab (ADAL) + MTX, leﬂunomide
(LEFT) + MTX, and cyclosporine. Relative clinical effectiveness
were estimated by an indirect comparison of published ACR
response rates adjusting for different study populations and
complemented with observational data. Quality adjusted life-
years (QALYs) were mapped from a disease severity measure
(Health Assessment Questionnaire [HAQ]) score. Average treat-
ment duration for biological agents, LFT + MTX, and CSA were
assumed to be 4.25, 4.10, and 1.70 years, respectively. Drug
acquisition costs were based on Taiwan’s National Health Insur-
ance fee schedule for 2007. Costs associated with drug adminis-
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